Skip to main content
The Egyptian Journal of Bronchology

Table 3 Pulmonary function and sputum profile among studied groups based on ICS use

From: Inhaled corticosteroid response in smoker versus non-smoker asthmatic patients: a cross-sectional study

 

Smokers

Ex-smokers

Non-smokers

Non ICS (n = 16)

ICS (n = 26)

P value

Non ICS (n = 13)

ICS (n = 17)

P value

No ICS (n = 35)

On ICS (n = 10)

P value

ACQ

  

0.23

  

0.38

  

< 0.001

 Well controlled

1 (6.3%)

4 (15.4%)

 

0

3 (17.6%)

 

16 (45.7%)

9 (90%)

 

 Partly controlled

4 (25%)

7 (26.9%)

 

5 (38.5%)

7 (41.2%)

 

9 (25.7%)

1 (10%)

 

 Uncontrolled

11 (68.7%)

15 (57.7%)

 

8 (61.5%)

7 (41.2%)

 

10 (28.6%)

0

 

Sputum cellularity

        

0.13

 No

1 (6.2%)

4 (15.4%)

0.15

1 (7.7%)

1 (5.9%)

0.28

19 (54.3%)

4 (40%)

 

 Mild

6 (37.5%)

10 (38.5%)

 

5 (38.5%)

8 (47%)

 

10 (28.6%)

5 (50%)

 

 Moderate

0

1 (3.8%)

 

0

1 (5.9%)

 

2 (5.7%)

1 (10%)

 

 High

9 (56.3%)

11 (42.3%)

 

7 (53.8%)

7 (41.2%)

 

4 (11.4%)

0

 

Alveolar macrophages

7 (44%)

12 (46.2%)

0.64

8 (61.5%)

7 (41.2%)

0.16

18 (51.4%)

5 (50%)

0.08

Eosinophils (%)

4.33 ± 1.95

2.99 ± 1.33

0.38

6.53 ± 2.13

4.73 ± 1.72

0.96

8.75 ± 2.57

2.61 ± 1.35

0.04

Neutrophils (%)

24.50 ± 4.93

17.83 ± 8.39

0.65

30.92 ± 3.60

11.57 ± 5.66

0.08

29.6 ± 6.91

7.15 ± 5.85

0.01

Histiocytes (%)

15.67 ± 6.08

18.33 ± 7.90

0.77

20.90 ± 3.85

14.73 ± 4.80

0.51

12.5 ± 2.43

11.14 ± 5.32

0.95

Lymphocytes (%)

12.50 ± 1.30

10.83 ± 1.48

0.12

16.36 ± 9.07

5.78 ± 4.26

0.19

8.33 ± 6.06

11.42 ± 3.21

0.66

Post-BD FEV1/FVC

69.36 ± 13.12

72.57 ± 11.32

0.45

68 ± 17.02

78.70 ± 9.45

0.08

77 ± 14.23

86.1 ± 12.58

0.04

Post-BD FEV-1

70.09 ± 15.78

73.23 ± 21.75

0.81

64.9 ± 25.83

88 ± 11.88

0.01

65.9 ± 25.9

87.47 ± 11.5

0.03

Post-BD FVC

91 ± 7.72

96.03 ± 4.94

0.68

79.77 ± 20.5

96 ± 3.93

0.02

83.2 ± 16.6

86.5 ± 11.55

0.73

Post-BD FEF25-75

50.55 ± 39.61

55.33 ± 29.64

0.75

47.16 ± 11.49

55.09 ± 36.2

0.90

40.22 ± 27

65.50 ± 17.59

0.03

TLC (%)

176.12 ± 65.89

99.75 ± 28.3

0.31

141.2 ± 3.49

132.67 ± 4.58

0.40

104.63 ± 19.7

102.78 ± 25.31

0.84

RV/TLC (%)

49.22 ± 15.86

38.67 ± 16.36

0.23

45.75 ± 25.12

42.50 ± 7.93

0.86

47.85 ± 18.38

44.72 ± 16.23

0.87

DICo (%)

82 ± 24.86

92.50 ± 24.74

0.60

86.60 ± 27.30

98 ± 26

0.58

83.67 ± 11.58

91.25 ± 31.98

0.68

Periostin

18.03 ± 6.63

10.45 ± 9.65

0.23

16.34 ± 7.89

11.43 ± 1.41

0.08

21.61 ± 2.59

11.41 ± 4.74

0.12

Eotaxin-2

578.77 ± 98.7

437.28 ± 64.58

0.87

200 ± 66.67

152.94 ± 55.91

0.23

163.33 ± 51.11

108.62 ± 2.03

0.21

  1. Data expressed as frequency (percentage), mean (SD). P value was significant if < 0.05
  2. ICS inhaled corticosteroid, ACQ asthma control questionnaire, BD bronchodilator, FEV-1 forced expiratory volume-1, FVC forced vital capacity, TLC total lung capacity
Back to article page